Impact of TheraWorx Foam on Symptom Relief in Thumb Arthritis

• Status: Completed
• Trial end date: 2020-08-01
• Target enrollment: 0
• Participant gender: All

Summary

Thumb carpometacarpal osteoarthritis (CMC OA) affects up to 33% of people over the age of 40, which leads to inflammation, pain, and weakness of the CMC joint. Treatment modalities are both conservative and surgical with surgical options including osteotomy, bone excision, ligament reconstruction, and various prosthetic implants. The conservative treatment options, however, are limited to NSAIDs and bracing or steroid injections.

Advances in topical therapies have the potential to deliver focused treatment to the CMC joint. Novel treatment of inflammation can potentially reduce inflammation and pain associated with progressing osteoarthritis. Theraworx Relief is an FDA registered foam that has theoretical impact on inflammation reduction in human subjects treated with the topical foam.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: John Fowler
• Treatments: Allantoin

Criteria

Inclusion Criteria:

1. Thumb CMC arthritis

2. greater than or equal to age 18

3. Interested in non-operative treatment of thumb arthritis

Exclusion Criteria:

1. Recent corticosteroid injection into the thumb joint

2. Non-English speaking

3. skin lesions or rashes on the thumb

4. current use of topical anti-inflammatory medications

5. concomitant thumb/wrist diagnoses that would impact the results (as determined by the PI)

6. known allergy to magnesium